# EDGAR Filing Document

**Accession Number:** 0001420822
**File Stem:** 0001104659-26-069621
**Filing Date:** 2026-6
**Character Count:** 9738
**Document Hash:** 0a5e6196ac2fa0961f76e2ed56bb5d5c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-069621.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0001104659-26-069621

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260529

**FILED AS OF DATE**: 20260602

**DATE AS OF CHANGE**: 20260602

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lanfear Dennis M
- **CENTRAL INDEX KEY:** 0001420822

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36721
- **FILM NUMBER:** 261058561

**MAIL ADDRESS:**
- **STREET 1:** C/O COHERUS BIOSCIENCES, INC.
- **STREET 2:** 333 TWIN DOLPHIN DRIVE, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Coherus Oncology, Inc.
- **CENTRAL INDEX KEY:** 0001512762
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 273615821
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** (650) 649-3530

**MAIL ADDRESS:**
- **STREET 1:** C/O DENNIS M. LANFEAR
- **STREET 2:** 333 TWIN DOLPHIN DR, SUITE 600
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Coherus BioSciences, Inc.
- **DATE OF NAME CHANGE:** 20130114

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioGenerics, Inc.
- **DATE OF NAME CHANGE:** 20110210

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lanfear Dennis M<br><sub>(Last) (First) (Middle)</sub><br>C/O COHERUS ONCOLOGY, INC.<br>333 TWIN DOLPHIN DRIVE, SUITE 600<br><sub>(Street)</sub><br>REDWOOD CITY, CA 94065<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-29 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President & CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Coherus Oncology, Inc. [ CHRS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $12.70 | 2026-05-29 |  | D |  |  | 200000 | <sup>(1)</sup> | 2027-08-06 | Common Stock | 200000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $10.05 | 2026-05-29 |  | D |  |  | 400000 | <sup>(1)</sup> | 2028-02-01 | Common Stock | 400000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $12.37 | 2026-05-29 |  | D |  |  | 450000 | <sup>(1)</sup> | 2029-01-11 | Common Stock | 450000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $17.73 | 2026-05-29 |  | D |  |  | 500000 | <sup>(1)</sup> | 2030-01-10 | Common Stock | 500000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $18.33 | 2026-05-29 |  | D |  |  | 500000 | <sup>(1)</sup> | 2031-01-23 | Common Stock | 500000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $17.60 | 2026-05-29 |  | D |  |  | 125000 | <sup>(1)</sup> | 2031-02-01 | Common Stock | 125000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $15.94 | 2026-05-29 |  | D |  |  | 402500 | <sup>(1)</sup> | 2032-01-04 | Common Stock | 402500 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $10.37 | 2026-05-29 |  | D |  |  | 402500 | <sup>(2)</sup> | 2033-01-05 | Common Stock | 402500 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $5.44 | 2026-05-29 |  | D |  |  | 225000 | <sup>(1)</sup> | 2033-06-13 | Common Stock | 225000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 200000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 200000 | <sup>(3)</sup> | 200000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 400000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 400000 | <sup>(3)</sup> | 400000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 450000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 450000 | <sup>(3)</sup> | 450000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 500000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 500000 | <sup>(3)</sup> | 500000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 500000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 500000 | <sup>(3)</sup> | 500000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 125000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 125000 | <sup>(3)</sup> | 125000 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 402500 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 402500 | <sup>(3)</sup> | 402500 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 402500 |  | <sup>(2)</sup> | 2036-05-29 | Common Stock | 402500 | <sup>(3)</sup> | 402500 | D |  |
| Stock Option (Right to Buy) | 1.59<sup>(4)</sup> | 2026-05-29 |  | A |  | 225000 |  | <sup>(1)</sup> | 2036-05-29 | Common Stock | 225000 | <sup>(3)</sup> | 225000 | D |  |

---

### Footnotes:

(1) The option is fully vested and exercisable.

(2) The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from January 5, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

(3) On May 29, 2026, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged.

(4) On May 29, 2026, the Issuer's stockholders approved an option repricing at an exercise price of $1.59 per share (the "Repricing") of the stock options held by current employees and other service providers previously priced at or over $5. The Repricing is subject to the Reporting Person remaining in service to the Issuer through May 29, 2027.

**Signature:** /s/ Bryan McMichael, as Attorney-in-Fact for Dennis M. Lanfear  
**Date:** 2026-06-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**